PartnershipUpdated on 23 April 2026
R&D collaboration for pre-clinical assets
About
CureRoot is actively seeking strategic R&D collaborations with global pharmaceutical companies to co-develop our high-potency pre-clinical assets. We offer our partners exclusive access to completely novel chemical matter derived from proprietary African plant scaffolds.
Through co-development, we aim to combine our discovery and early-validation capabilities with our partners' clinical development and regulatory expertise, accelerating our oncology and infectious disease candidates through IND-enabling studies and into human trials.
Organisation
Similar opportunities
Partnership
Do Youn Chun
Chief Technical Officer at AT-31 BIO Inc.
Daegu, South Korea
Expertise
Toxicology and DMPK Consultancy
Magali-Anne Maizieres
Electrophysiology Scientist at ApconiX
Manchester, United Kingdom
Partnership
Sandra von Meier
Head of Business Development Life Science at Terra Quantum AG
Munich, Germany